Imatinib is a revolutionary targeted therapy used to treat certain types of cancer, most notably chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It works by inhibiting specific tyrosine kinases—enzymes responsible for the uncontrolled growth of cancer cells—thereby halting disease progression at a molecular level.

This oral medication has transformed the prognosis for patients with CML, turning what was once a life-threatening illness into a manageable chronic condition. Imatinib is generally well tolerated, with common side effects including nausea, muscle cramps, and fatigue.

With the expiration of the original patent, many manufacturer of imatinib have entered the global market, producing high-quality generic versions that are more affordable and accessible. This increased availability has significantly broadened patient access, particularly in low- and middle-income countries, and continues to play a critical role in the global fight against cancer.